Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib

Lorlatinib—a ROS1/ALK inhibitor—is currently undergoing clinical trials for the treatment of non-small cell lung cancers. Here the authors develop synthetic routes to11C- and 18F-labelled lorlatinib, with subsequent PET imaging showing good blood brain barrier permeability in non-human primates.

Guardado en:

Detalles Bibliográficos
Autores principales:	Thomas Lee Collier, Marc D. Normandin, Nickeisha A. Stephenson, Eli Livni, Steven H. Liang, Dustin W. Wooten, Shadi A. Esfahani, Michael G. Stabin, Umar Mahmood, Jianqing Chen, Wei Wang, Kevin Maresca, Rikki N. Waterhouse, Georges El Fakhri, Paul Richardson, Neil Vasdev
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/c6a81b2a14fd4e259767853846c7c586
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib

Ejemplares similares